The 19 references in paper I. Bobkova N., L. Kozlovskaya V., A. Cygin N., E. Shilov M., И. Бобкова Н., Л. Козловская В., А. Цыгин Н., Е. Шилов М. (2014) “Клинические рекомендации по диагностике и лечению мембранозной нефропатии // Clinical practice guidelines for diagnosis and treatment membranous nephropathy” / spz:neicon:nefr:y:2014:i:4:p:93-100

1
Аткинс РК. Гломерулонефриты. Нефрология и диализ 2000; 2 (4)
(check this in PDF content)
2
Захарова ЕВ. Роль циклоспорина в лечении идиопатического гломерулонефрита и волчаночного нефрита. Нефрология и диализ 2010; 12(2): 126-141
(check this in PDF content)
3
Козловская ЛВ. Хронический гломерулонефрит: аргументы в пользу циклоспорина. Клин нефрол 2010; 3: 56-61
(check this in PDF content)
4
Мухин НА, Козловская ЛВ. Мембранозная нефропатия: как дифференцировать первичный и вторичный варианты. Клин нефрол 2009; 2: 75-78
(check this in PDF content)
5
Смирнов АВ. Лечение гломерулопатий циклоспорином: правильный подход с неверным обоснованием. Нефрология 2010; 14 (4): 9-22
(check this in PDF content)
6
Смирнов АВ. Практические вопросы применения циклоспорина в лечении гломерулопатий. Нефрология 2010; 14 (4): 96-102
(check this in PDF content)
7
Beck LH, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Eng J Med 2009; 361:11-21
(check this in PDF content)
8
Beck LH, Fervenza FC, Beck DM et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011; 22: 1543-1550
(check this in PDF content)
9
Bomback AS, Derebail VK, McGregor JG. Rituximab therapy for membranous nephropathy. Clin J Am Soc Nephol 2009; 4: 734-744
(check this in PDF content)
10
Branten AJ. Mycophenolate mofetil in idiopathic membranous nephropathy. Clinical trial with comparison to a historical control group treated with cyclophosphamide. Am J Kidney Dis 2007; 50: 248-256
(check this in PDF content)
11
Cattran DC. Cyclosporin in idiopathic glomerular disease associated with the nephritic syndrome: workshop recommendations. Kidney Int 2007; 72(12): 1429-1447
(check this in PDF content)
12
Cattran DC. North America nephrotic syndrome study G: Cyclosporin in patients with steroid resistant membranous nephropathy: a randomize trial. J Am Soc Nephrol 2001; 59: 1484-1490
(check this in PDF content)
13
Cattran DC. Management of Idiopathic membranous nephropathy. What and When for treatment. J Am Soc Nephrol 2005; 16: 1188-1194
(check this in PDF content)
14
Debeick H, Lefeu F, Kemper MJ et al. Early childhood membranous nephropathy induced by antibodies to cationic bovine serum albumin. N Eng J Med 2011; 364: 2101-2110
(check this in PDF content)
15
Glassock RJ. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis 2010; 38: 157–167
(check this in PDF content)
16
Glassock R.J. Diagnosis and natural course of membranous nephropathy. Sem Nephrol. 2003; 23: 324-332.
(check this in PDF content)
17
Kidney Diseases: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for glomerulonephritis. Kidney Int Suppl 2012; 2(2):139-274
(check this in PDF content)
18
Ponticelli C. Membranous nephropathy. J Nephrol 2007; 20(3): 268-287
(check this in PDF content)
19
Ronco P, Debeic H. Advances in membranous nephropathy: success stories of a long journey. Clin and Experiment Pharmacol and Physiol 2011; 38: 410–416 Авторы заявляют об отсутствии конфликта интересов. Поступила в редакцию: 10.03.2014 г. Принята в печать: 29.05.2014 г.
(check this in PDF content)